Bayer plans to put $2.2 billion toward the construction of a new drug production site in Ohio, with a starting focus in oncology, cardiovascular and kidney therapies.
Described as a modular campus that will span drug substance and product manufacturing, the site outside Columbus in New Albany is slated to create about 600 new jobs. The project is part of a broader $7 billion that Bayer has set aside for R&D and manufacturing in the U.S. over the past five years.
“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” CEO Bill Anderson said in a statement…